Fig. 4: Down- and upregulation of specific subsets of genes by lymphatic endothelial cells treated with PEVs assessed by RNA-sequencing and qPCR analysis. | Communications Biology

Fig. 4: Down- and upregulation of specific subsets of genes by lymphatic endothelial cells treated with PEVs assessed by RNA-sequencing and qPCR analysis.

From: Platelet extracellular vesicles preserve lymphatic endothelial cell integrity and enhance lymphatic vessel function

Fig. 4

Human LECs were treated for 24 h with PEVs. a Volcano plot of transcriptomic analysis was performed in human LEC. Y axis =  p-value (-LOG10) of the gene expression. X axis = fold change PEVs/Control (LOG2) of gene expression. Each gene is represented by a dot. Significant down- and upregulated genes in PEV-treated LECs are depicted in blue and red, respectively. mRNA expression in human LECs was also performed by qPCR analysis for (b) F11R, (c) PROX1, (d) FLT4, (e) TJP1 and (f) CDH5 mRNA. Human LECs were also treated for 24 h with rbEVs, and mRNA expression of (g) CDH5, (h) F11R, (i) PROX1 and (j) FLT4 was subsequently measured by qPCR analysis. Each point (n) represents cells treated with PEVs produced from a single donor ± SEM. PEVs: platelet extracellular vesicles; rbEVs: red blood cell extracellular vesicles; F11R: F11 Receptor; PROX1: Prospero homeobox protein 1; FLT4: Fms-related tyrosine kinase 4; TJP1: Tight junction protein-1; CDH5: cadherin 5.

Back to article page